pubmed-article:11222501 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0039195 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0019629 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0596402 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0024518 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C1368327 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0456387 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
pubmed-article:11222501 | lifeskim:mentions | umls-concept:C0443177 | lld:lifeskim |
pubmed-article:11222501 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:11222501 | pubmed:dateCreated | 2001-3-6 | lld:pubmed |
pubmed-article:11222501 | pubmed:abstractText | The CD94/NKG2A heterodimer is an inhibitory receptor expressed on a subset of mouse NK cells. CD94/NKG2A recognizes the non-classical MHC class I (class Ib) molecule Qa-1(b) and inhibits NK cytotoxicity. Qa-1(b) presents a peptide derived from the leader sequence of classical MHC class I molecules. Here, we examined the role of CD94/NKG2A in T cell-mediated cytotoxicity. Soluble tetrameric Qa-1(b) bound to almost all CD8(+), but not CD4(+), T cells. This binding seems to be mediated by CD8, because COS cells transfected with CD8 also bound Qa-1(b) tetramer. Therefore, the expression of CD94/NKG2 in T cells was further examined by single-cell RT-PCR. Most murine CD8(+) T cells constitutively expressed CD94 and NKG2A transcripts, whereas they were not detected in CD4(+) T cells. Co-expression of Qa-1(b) and D(k) on target cells significantly inhibited cytotoxicity of D(k)-specific cytotoxic T lymphocytes generated by mixed lymphocyte reaction, indicating that Qa-1(b) on antigen-presenting cells interacts with CD94/NKG2A on CD8 T cells and regulates classical MHC class I-restricted cytotoxic T cells. These results suggest a significant role of CD94/NKG2A as an inhibitory receptor on CD8(+) T cells. | lld:pubmed |
pubmed-article:11222501 | pubmed:language | eng | lld:pubmed |
pubmed-article:11222501 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11222501 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11222501 | pubmed:month | Mar | lld:pubmed |
pubmed-article:11222501 | pubmed:issn | 0953-8178 | lld:pubmed |
pubmed-article:11222501 | pubmed:author | pubmed-author:KubotaAA | lld:pubmed |
pubmed-article:11222501 | pubmed:author | pubmed-author:TakeiFF | lld:pubmed |
pubmed-article:11222501 | pubmed:author | pubmed-author:SalcedoMM | lld:pubmed |
pubmed-article:11222501 | pubmed:author | pubmed-author:LevyD HDH | lld:pubmed |
pubmed-article:11222501 | pubmed:author | pubmed-author:LohwasserSS | lld:pubmed |
pubmed-article:11222501 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11222501 | pubmed:volume | 13 | lld:pubmed |
pubmed-article:11222501 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11222501 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11222501 | pubmed:pagination | 321-7 | lld:pubmed |
pubmed-article:11222501 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:meshHeading | pubmed-meshheading:11222501... | lld:pubmed |
pubmed-article:11222501 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11222501 | pubmed:articleTitle | The non-classical MHC class I molecule Qa-1(b) inhibits classical MHC class I-restricted cytotoxicity of cytotoxic T lymphocytes. | lld:pubmed |
pubmed-article:11222501 | pubmed:affiliation | Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, BC V5Z 1L3 Canada. | lld:pubmed |
pubmed-article:11222501 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11222501 | pubmed:publicationType | Comparative Study | lld:pubmed |
pubmed-article:11222501 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11222501 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11222501 | lld:pubmed |